Sun Pharma gets U.S. nod for prostate cancer drug

BANGALORE, July 7 (Reuters) - India's Sun Pharmaceutical Industries Ltd (SUN.BO) said on Tuesday it had received approval from the U.S. Food and Drug Administration to launch generic version of AstraZeneca Plc's (AZN.L) prostate cancer drug Casodex.

The Indian drug maker said in a statement that AstraZeneca (AZN.L) had annual sales of Casodex of $314 million in the United States.

Ahead of the announcement, shares in Sun Pharma rose 1.2 percent to 1,143.35 rupees in the main Mumbai market .BSESN that ended 0.9 percent higher. (Reporting by Sumeet Chatterjee; Editing by David Cowell)